Eli Lilly Tirzepatide H1 2026 Sales Reach $27.7 Billion (+88% YoY) as Lead Over Novo Nordisk Semaglutide Portfolio Widens to $10.2 Billion
H1 2026 GLP-1 franchise reporting places Eli Lilly (NYSE: LLY) tirzepatide (Mounjaro plus Zepbound) at nearly $27.7 billion in first-half revenue, an 88% year-over-year increase, versus Novo Nordisk (NYSE: NVO) semaglutide (Ozempic plus Wegovy plus Rybelsus plus Wegovy pill) at approximately $17.5 billion. The revenue gap between the two GLP-1 leaders has widened from under $2 billion at the same point last year to $10.2 billion, driven by Zepbound share gains in U.S. obesity following SURMOUNT-5 superiority data over Wegovy, Mounjaro upside in international markets (China +93% CER, Rest of World +136%), Foundayo (orforglipron) first commercial quarter contribution of $98 million, and semaglutide patent expiries approaching in select markets (generic Ozempic expected in Canada). Novo has cut 12,000 positions in H1 2026 and lowered gross margin outlook to 78%, while Lilly raised full-year 2026 revenue guidance to $85-87 billion.